According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 8.4% and a 36.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $100.14.
The company has a one-year high of $94.50 and a one-year low of $61.91. Currently, Incyte has an average volume of 2.18M.
Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of INCY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.
Read More on INCY:
- Deutsche Bank Sticks to Their Hold Rating for M&G Plc (MGPUF)
- J.P. Morgan Reaffirms Their Hold Rating on Clarkson (CKNHF)
- Deutsche Bank Reaffirms Their Buy Rating on Fevertree Drinks (FQVTF)
- Deutsche Bank Believes Standard Chartered (SCBFF) Won’t Stop Here
- Deutsche Bank Remains a Buy on Royal Mail (ROYMF)